Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


03.12.2018

1 Am J Clin Oncol
3 Ann Oncol
1 Ann Surg Oncol
2 BMC Cancer
1 Br J Cancer
1 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
12 Breast Cancer Res Treat
2 Breast J
2 Cancer
2 Cancer Epidemiol Biomarkers Prev
5 Clin Breast Cancer
1 Clin Cancer Res
2 Eur J Cancer
1 Gene
4 Int J Cancer
1 J Biol Chem
1 J Clin Oncol
1 J Natl Cancer Inst
2 J Surg Oncol
1 Lancet
2 Oncogene
1 Oncol Rep
1 Oncology (Williston Park)
1 PLoS Genet
5 PLoS One
1 Proc Natl Acad Sci U S A
2 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. LEONE J, Zwenger AO, Leone BA, Vallejo CT, et al
    Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
    Am J Clin Oncol. 2018 Nov 28. doi: 10.1097/COC.0000000000000497.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. ADAMS S, Schmid P, Rugo HS, Winer EP, et al
    Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209693. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. ADAMS S, Loi S, Toppmeyer D, Cescon DW, et al
    Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209695. doi: 10.1093.
    PubMed     Text format     Abstract available

  4. EVRON E, Ben-David AM, Goldberg H, Fried G, et al
    Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer.
    Ann Oncol. 2018 Nov 23. pii: 5200725. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  5. VAN DER NOORDAA MEM, Vrancken Peeters MTFD
    ASO Author Reflections: Reducing Axillary Lymph Node Dissections in Node-Positive Breast Cancer Patients.
    Ann Surg Oncol. 2018 Nov 26. pii: 10.1245/s10434-018-6975.
    PubMed     Text format    


    BMC Cancer

  6. CIFU G, Power MC, Shomstein S, Arem H, et al
    Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review.
    BMC Cancer. 2018;18:1163.
    PubMed     Text format     Abstract available

  7. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Text format     Abstract available


    Br J Cancer

  8. TIAN J, Raffa FA, Dai M, Moamer A, et al
    Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0287.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  9. EL-SAGHEER G, Gayyed M, Ahmad A, Abd El-Fattah A, et al
    Expression of chemerin correlates with a poor prognosis in female breast cancer patients.
    Breast Cancer (Dove Med Press). 2018;10:169-176.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  10. MERINO VF, Cho S, Nguyen N, Sadik H, et al
    Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Breast Cancer Res. 2018;20:145.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  11. WALSH EM, Shalaby A, O'Loughlin M, Keane N, et al
    Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Breast Cancer Res Treat. 2018 Nov 28. pii: 10.1007/s10549-018-5066.
    PubMed     Text format     Abstract available

  12. HOLLERN DP, Contreras CM, Dance-Barnes S, Silva GO, et al
    A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5061.
    PubMed     Text format     Abstract available

  13. SHTAM T, Naryzhny S, Samsonov R, Karasik D, et al
    Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5043.
    PubMed     Text format     Abstract available

  14. GIBBS LD, Chaudhary P, Mansheim K, Hare RJ, et al
    ANXA2 expression in African American triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5030.
    PubMed     Text format     Abstract available

  15. ABOUEGYLAH M, Braunstein LZ, Alm El-Din MA, Niemierko A, et al
    Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5053.
    PubMed     Text format     Abstract available

  16. ROZNER RN, Freites-Martinez A, Shapiro J, Geer EB, et al
    Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
    Breast Cancer Res Treat. 2018 Nov 22. pii: 10.1007/s10549-018-4996.
    PubMed     Text format     Abstract available

  17. WANG J, Xu B, Wang W, Zhai X, et al
    Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5047.
    PubMed     Text format     Abstract available

  18. IGNATOV T, Claus M, Nass N, Haybaeck J, et al
    G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5064.
    PubMed     Text format     Abstract available

  19. LOO LWM, Gao C, Shvetsov YB, Okoro DR, et al
    MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5065.
    PubMed     Text format     Abstract available

  20. CHASAMPALIOTI M, Green AR, Ellis IO, Rakha EA, et al
    Connexin 43 is an independent predictor of patient outcome in breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5063.
    PubMed     Text format     Abstract available

  21. HENRY DA, Lee MC, Almanza D, Ahmed KA, et al
    Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5057.
    PubMed     Text format     Abstract available

  22. CRAZE ML, El-Ansari R, Aleskandarany MA, Cheng KW, et al
    Glutamate dehydrogenase (GLUD1) expression in breast cancer.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5060.
    PubMed     Text format     Abstract available


    Breast J

  23. REBLIN M, Kasting ML, Nam K, Scherr CL, et al
    Health beliefs associated with readiness for genetic counseling among high risk breast cancer survivors.
    Breast J. 2018 Nov 28. doi: 10.1111/tbj.13165.
    PubMed     Text format     Abstract available

  24. BORDERS MH
    Breast MRI and BI-RADS category 3: Is it appropriate?
    Breast J. 2018;24:107-108.
    PubMed     Text format    


    Cancer

  25. CARROLL JE, Van Dyk K, Bower JE, Scuric Z, et al
    Cognitive performance in survivors of breast cancer and markers of biological aging.
    Cancer. 2018 Nov 26. doi: 10.1002/cncr.31777.
    PubMed     Text format     Abstract available

  26. VAN DYK K, Crespi CM, Bower JE, Castellon SA, et al
    The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment.
    Cancer. 2018 Nov 28. doi: 10.1002/cncr.31858.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  27. XIE J, Xu Z
    A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2018 Nov 28. pii: 1055-9965.EPI-18-0591.
    PubMed     Text format     Abstract available

  28. GUAN Z, Yu H, Cuk K, Zhang Y, et al
    Whole-blood DNA methylation markers in early detection of breast cancer: a systematic literature review.
    Cancer Epidemiol Biomarkers Prev. 2018 Nov 28. pii: 1055-9965.EPI-18-0378.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  29. XIAO YL, Wang K, Liu Q, Li J, et al
    Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.
    Clin Breast Cancer. 2018 Oct 4. pii: S1526-8209(18)30521.
    PubMed     Text format     Abstract available

  30. CHEN W, Zhang J, Huang L, Chen L, et al
    Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Clin Breast Cancer. 2018 Nov 1. pii: S1526-8209(18)30500.
    PubMed     Text format     Abstract available

  31. BAWAZIR A, Bashateh N, Jradi H, Breik AB, et al
    Breast Cancer Screening Awareness and Practices Among Women Attending Primary Health Care Centers in the Ghail Bawazir District of Yemen.
    Clin Breast Cancer. 2018 Sep 20. pii: S1526-8209(18)30429.
    PubMed     Text format     Abstract available

  32. CHEN H, Zhang M, Wang M, Zhang P, et al
    Immediate Breast Reconstruction in De Novo Metastatic Breast Cancer: An Analysis of 563 Cases Based on the SEER Database.
    Clin Breast Cancer. 2018 Nov 5. pii: S1526-8209(18)30678.
    PubMed     Text format     Abstract available

  33. BRANDINI DA SILVA FC, Jose da Silva J, Sarri AJ, Paiva CE, et al
    Comprehensive Validation Study of Quality-of-Life Questionnaire Using Objective Clinical Measures: Breast Cancer Treatment Outcome Scale (BCTOS), Brazilian Portuguese Version.
    Clin Breast Cancer. 2018 Oct 27. pii: S1526-8209(18)30512.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  34. SHIINO S, Matsuzaki J, Shimomura A, Kawauchi J, et al
    Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer.
    Clin Cancer Res. 2018 Nov 27. pii: 1078-0432.CCR-18-1414.
    PubMed     Text format     Abstract available


    Eur J Cancer

  35. SINGER CF, Balmana J, Burki N, Delaloge S, et al
    Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
    Eur J Cancer. 2018;106:54-60.
    PubMed     Text format     Abstract available

  36. RUTGERS E, Balmana J, Beishon M, Benn K, et al
    European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.
    Eur J Cancer. 2018;106:45-53.
    PubMed     Text format     Abstract available


    Gene

  37. ORANGI E, Motovali-Bashi M
    Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women.
    Gene. 2018;687:272-279.
    PubMed     Text format     Abstract available


    Int J Cancer

  38. BULANOVA DR, Helenius M, Sokolenko AP, Kuznetsov SG, et al
    Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32013.
    PubMed     Text format    

  39. PANDEY K, An HJ, Kim SK, Lee SA, et al
    Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32020.
    PubMed     Text format     Abstract available

  40. KLASCHIK K, Hauke J, Neidhardt G, Trankle C, et al
    The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32016.
    PubMed     Text format    

  41. TORRES D, Lorenzo Bermejo J, Garcia Mesa K, Gilbert M, et al
    Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32023.
    PubMed     Text format     Abstract available


    J Biol Chem

  42. GAYLE SS, Sahni JM, Webb BM, Weber-Bonk KL, et al
    Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
    J Biol Chem. 2018 Nov 27. pii: RA118.004712. doi: 10.1074/jbc.RA118.004712.
    PubMed     Text format     Abstract available


    J Clin Oncol

  43. RUHSTALLER T, Giobbie-Hurder A, Colleoni M, Jensen MB, et al
    Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
    J Clin Oncol. 2018 Nov 26:JCO1800440. doi: 10.1200/JCO.18.00440.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  44. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Surg Oncol

  45. BERGER ER, Bilimoria KY, Kinnier CV, Minami CA, et al
    Assessment of hospital-level adjusted breast cancer sentinel lymph node positivity rates.
    J Surg Oncol. 2018 Nov 27. doi: 10.1002/jso.25294.
    PubMed     Text format     Abstract available

  46. PANCHAL H, Pilewskie ML, Sheckter CC, Albornoz CR, et al
    National trends in contralateral prophylactic mastectomy in women with locally advanced breast cancer.
    J Surg Oncol. 2018 Nov 27. doi: 10.1002/jso.25315.
    PubMed     Text format     Abstract available


    Lancet

  47. SHEIKH S, Sasieni P
    When should the errors in the UK's breast screening programme have been spotted?
    Lancet. 2018;391:2319-2320.
    PubMed     Text format    


    Oncogene

  48. VARGAS G, Bouchet M, Bouazza L, Reboul P, et al
    ERRalpha promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0579.
    PubMed     Text format     Abstract available

  49. ZHAO H, Martin E, Matalkah F, Shah N, et al
    Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
    Oncogene. 2018 Nov 22. pii: 10.1038/s41388-018-0574.
    PubMed     Text format     Abstract available


    Oncol Rep

  50. JING X, Liang H, Hao C, Yang X, et al
    Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6887.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  51. JERZAK KJ, Raphael J, Desautels DN, Blanchette PS, et al
    Bone-Targeted Therapy in Early Breast Cancer.
    Oncology (Williston Park). 2018;32:562-9.
    PubMed     Text format     Abstract available


    PLoS Genet

  52. JADALIHA M, Gholamalamdari O, Tang W, Zhang Y, et al
    A natural antisense lncRNA controls breast cancer progression by promoting tumor suppressor gene mRNA stability.
    PLoS Genet. 2018;14:e1007802.
    PubMed     Text format     Abstract available


    PLoS One

  53. GROSSE FRIE K, Kamate B, Traore CB, Ly M, et al
    Factors associated with time to first healthcare visit, diagnosis and treatment, and their impact on survival among breast cancer patients in Mali.
    PLoS One. 2018;13:e0207928.
    PubMed     Text format     Abstract available

  54. GOKAL K, Munir F, Ahmed S, Kancherla K, et al
    Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial.
    PLoS One. 2018;13:e0206874.
    PubMed     Text format     Abstract available

  55. SUN L, Legood R, Dos-Santos-Silva I, Gaiha SM, et al
    Global treatment costs of breast cancer by stage: A systematic review.
    PLoS One. 2018;13:e0207993.
    PubMed     Text format     Abstract available

  56. DAVIS M, Tripathi S, Hughley R, He Q, et al
    AR negative triple negative or "quadruple negative" breast cancers in African American women have an enriched basal and immune signature.
    PLoS One. 2018;13:e0196909.
    PubMed     Text format     Abstract available

  57. BALOGH KN, Templeton DJ, Cross JV
    Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses.
    PLoS One. 2018;13:e0197702.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  58. MATSUNUMA R, Chan DW, Kim BJ, Singh P, et al
    DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.
    Proc Natl Acad Sci U S A. 2018 Nov 29. pii: 1810598115.
    PubMed     Text format     Abstract available


    Radiother Oncol

  59. KARAGIANNIS E, Leczynski A, Tselis N, Psanis E, et al
    Inverse planning and inverse implanting for breast interstitial brachytherapy. Introducing a new anatomy specific breast interstitial template (ASBIT).
    Radiother Oncol. 2018;128:421-427.
    PubMed     Text format     Abstract available

  60. HOEKSTRA N, Fleury E, Merino Lara TR, van der Baan P, et al
    Long-term risks of secondary cancer for various whole and partial breast irradiation techniques.
    Radiother Oncol. 2018;128:428-433.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: